The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesI-ELISA: 1/51200 end point titre. Valproic acid conjugated to BSA on the solid phase.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceValproic acid, valproate sodium and divalproex belong to the group of medicines called anticonvulsants, used to control certain types of seizures in the treatment of epilepsy. Also, valproic acid relieves histone deacetylases (HDACs) dependent transcriptional repression and causes hyperacetylation of histones in cultured cells and in vivo. Valproic acid inhibits HDAC activity in vitro, most probably by binding to the catalytic centre of HDACs. Most importantly, valproic acid induces differentiation of carcinoma cells, transformed haematopoietic progenitor cells and leukaemic blasts from acute myeloid leukaemia patients. Moreover, tumour growth and metastasis formation are significantly reduced in animal experiments. Therefore, valproic acid might serve as an effective drug for cancer therapy.
2methylbutyryl coa dehydrogenase antibody
2methylbutyryl coenzyme a dehydrogenase antibody
References for Anti-Valproic Acid antibody [10-115.2] (ab40986)
has not yet been referenced specifically in any publications.
Publishing research using ab40986? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"